Co-Diagnostics (NASDAQ:CODX – Get Free Report) and SBC Medical Group (NASDAQ:SBC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Risk and Volatility
Co-Diagnostics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Earnings and Valuation
This table compares Co-Diagnostics and SBC Medical Group”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $620,000.00 | 11.44 | -$46.90 million | ($18.92) | -0.10 |
| SBC Medical Group | $173.61 million | 1.71 | $50.99 million | $0.39 | 7.41 |
SBC Medical Group has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 89.5% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for Co-Diagnostics and SBC Medical Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 1 | 2 | 1 | 0 | 2.00 |
| SBC Medical Group | 0 | 1 | 2 | 0 | 2.67 |
Co-Diagnostics presently has a consensus price target of $67.50, indicating a potential upside of 3,326.40%. SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 194.12%. Given Co-Diagnostics’ higher probable upside, research analysts clearly believe Co-Diagnostics is more favorable than SBC Medical Group.
Profitability
This table compares Co-Diagnostics and SBC Medical Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -6,760.63% | -164.92% | -141.15% |
| SBC Medical Group | 24.09% | 15.90% | 11.61% |
Summary
SBC Medical Group beats Co-Diagnostics on 11 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About SBC Medical Group
SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
